Taste neophobia is a feeding system defense mechanism that limits consumption of an unknown, and therefore potentially dangerous, edible until the post-ingestive consequences are experienced. We found that transient pharmacological inhibition (induced with the GABA agonists baclofen and muscimol) of the gustatory thalamus (GT; Experiment 1), but not medial amygdala (MeA; Experiment 2), during exposure to a novel saccharin solution attenuated taste neophobia. In Experiment 3 we found that inhibition of MeA neurons (induced with the chemogenetic receptor hM4DGi) enhanced the expression of taste neophobia whereas excitation of MeA neurons (with hM3DGq) had no influence of taste neophobia. Overall, these results refine the temporal involvement of the GT in the occurrence of taste neophobia and support the hypothesis that neuronal excitation in the GT is necessary for taste neophobia. Conversely, we show that chemogenetically, but not pharmacologically, inhibiting MeA neurons is sufficient to exaggerate the expression of taste neophobia.
Introduction
Feeding, particularly in the case of animals that forage for a varied diet, can be a dangerous business: many potential food items, plants and animals, have developed predation defense mechanisms involving toxicity (Cook, Ralphs, Welch, & Stegelmeier, 2009; Evans & Schmidt, 1990; Glendinning, 2007; Stegelmeier et al., 1999 ). There are two major feeding system defense mechanisms: taste neophobia and conditioned taste aversion (CTA). Taste neophobia serves to limit the ingestion of novel, and therefore potentially toxic, foods (Barnett, 1963; Corey, 1978; Domjan, 2018; Rozin, 1976 , for reviews see Reilly, 2018a) . Taste neophobia limits the palatability of novel foods thereby increasing the chances of survival by minimizing the dose (amount consumed) of any toxic compound ingested (Lin, Amodeo, Arthurs & Reilly, 2012a) . If consumption of a novel food (conditioned stimulus) is followed by aversive effects (unconditioned stimulus; US) CTA causes that food to become less palatable and limits intake in future encounters (for reviews see Barker, Best & Domjan, 1977; Braveman & Bronstein, 1985; Milgram, Krames & Alloway, 1977; Reilly & Schachtman, 2009) . Taste neophobia modulates the rate of CTA acquisition by setting the initial level of palatability, and thereby intake, for a novel tastant. Also, CTAs are less readily acquired by familiar foods, a phenomenon termed latent inhibition (Lubow, 1989 (Lubow, , 2009 ).
Thus, understanding the neural substrates of taste neophobia has broad implications for the understanding of ingestive behavior (for a review see Reilly, 2018b) .
Research in our laboratory has implicated four structures in taste neophobia: basolateral amygdala (BLA), gustatory insular cortex (GC), gustatory thalamus (GT), and medial amygdala (MeA). Bilateral lesions of either the BLA or GC cause an attenuation of taste neophobia and a latent inhibition-like delay of CTA acquisition (Lin, Arthurs & Reilly, 2011 Lin, Roman, St. Andre & Reilly, 2009; Roman & Reilly, 2007; St. Andre & Reilly, 2007) . Furthermore, asymmetrical unilateral lesions of the BLA and GC cause a taste neophobia deficit indicating these structures are components within a functional unit . Arthurs & Reilly (2013) found that the GT was also necessary for taste neophobia but that the same lesion had no influence on the rate of CTA acquisition. An examination of the literature revealed a similar pattern of results for MeA lesions: an attenuation of taste neophobia ) that did not produce a delay in CTA acquisition (e.g., Aggleton, Petrides & Iversen, 1981; Meliza, Leung & Rogers, 1981; Rollins, Stines, McGuire & King, 2001 ; for a review see Reilly & Bornovalova, 2005) . The fact that lesions of different structures can cause a similar attenuation of taste neophobia while having different influences on CTA acquisition suggests that taste neophobia has multiple behavioral components that are governed by https://doi.org/10.1016/j.nlm.2018.10.004 Received 13 June 2018; Received in revised form 13 September 2018; Accepted 11 October 2018 different neural circuits. We know the BLA and GC form a functional unit underlying taste neophobia, but the roles of the GT and MeA are less well understood.
To extend our results with permanent lesions, we sought to employ pharmacological inhibition via intracranial infusions of a GABA agonist cocktail (baclofen and muscimol; BM) as a transient inhibition (e.g., Arguello et al., 2017; Majchrzak & Di Scala, 2000) to refine our understanding of the temporal involvement of the GT and MeA in taste neophobia. Intracranial BM infusions rapidly suppress neuronal activity, an effect that lasts for over 45-min (Baker & Ragozzino, 2014; Kawabe, Chitravanshi, Kawabe & Sapru, 2008; McMullan & Pilowsky, 2012) . Taste neophobia occurs during the initial encounter with a novel tastant and so the primary focus of the present work is how the neural manipulations influence performance on Trial 1. Thus, infusions were done before the first exposure to a novel tastant followed on subsequent trials by drug free tastant access. Based on our lesion studies we expected that pharmacological inhibition of either the GT (Experiment 1A) or the MeA (Experiment 2) during the presentation of a novel tastant should result in attenuated taste neophobia. The results of Experiment 1A encouraged the conduct of a follow-up experiment (1B) in which BM was infused after the first exposure to a novel taste. Experiment 2 yielded a null result, potentially due to technical challenges, which led us to conduct Experiment 3 using chemogenetic tools to manipulate MeA neurons.
As noted, lesions of the MeA attenuate taste neophobia. However, neurons in the MeA, unlike cells in the GT, do not show elevated levels of Fos excitation consequent to ingestion of a novel taste (Lin, Roman, Arthurs & Reilly, 2012b) . This pattern of results encourages the view that inhibition of MeA neurons, a type of activity that is not detectable by Fos (e.g., Kovács, 2008; Stark, Davies, Williams, & Luckman, 2006) , may be critical for taste neophobia. This hypothesis was investigated in Experiment 3 using a chemogenetic approach to broadly inhibit (or excite) MeA neurons (Armbruster, Li, Pausch, Herlitze & Roth, 2007; Roth, 2016) . To allow the detection of a chemogenetic-induced increase or decrease in taste neophobia, a lower concentration of saccharin was used in Experiment 3 than in Experiments 1 and 2. Three groups of animals were prepared with bilateral transfections of MeA neurons with a virus containing genetic material encoding either an inert fluorophore, an excitatory or an inhibitory chemogenetic receptor. On the first trial of Experiment 3, animals were injected with clozapine-N-oxide (CNO; a ligand for the chemogenetic receptors) prior to the presentation of the novel saccharin solution to test the effects of modulating MeA neuron activity on the expression of taste neophobia.
The simplicity of the chemogenetic approach, relative to intracranial infusions, also had the benefit of allowing us to use lick pattern analysis in Experiment 3 to evaluate changes in taste palatability. When drinking, rats will normally produce sustained runs of licks that can be grouped into clusters of rapid licks separated by pauses of less than 0.5 s (Davis, 1989) . Cluster size (i.e., the mean number of licks per cluster) can be used to measure taste palatability independent of intake (Davis, 1996 (Davis, , 1998 Davis & Smith, 1992 ; for a review see Dwyer, 2012) . To wit, as the concentration of a sucrose solution increases so too does cluster size; however, concentration dependent intake follows an inverted parabolic trajectory (Hsiao & Fan, 1993; Spector, Klumpp & Kaplan, 1998) . Cluster size also shows a linear decrease in response to increasing concentrations of a bitter tastant (e.g., quinine; Hsiao & Fan, 1993; Spector & St. John, 1998) . Cluster size has also been used to detect increased palatability during the habituation of taste neophobia (Lin et al., 2012a) and downshifts in palatability in response to CTAs acquired to illness-inducing stimuli and drugs of abuse (Arthurs, Lin, Amodeo & Reilly, 2012; Arthurs & Reilly, 2013; Baird, St. John, Nguyen, 2005; Dwyer, Boakes & Hayward, 2008; Kent, Cross-Mellor, Kavaliers & Ossenkopp, 2002 
Surgery
All rats were anesthetized with a mixture of ketamine and xylazine (100:10 mg/kg, IP) and secured in a stereotaxic frame. Twenty-three rats were implanted with bilateral guide cannula (22 gauge; Plastics One, Roanoke, VA) targeted 2 mm dorsal to the GT (AP −3.7, ML ± 0.8, DV −4.3) and would serve in either the experimental group (BM) or a control subgroup (Saline). The remaining animals formed a second control subgroup (Anesthesia; n = 10) that was anesthetized and placed in the stereotaxic frame to control for exposure to anesthesia and potential nerve damage induced by ear bars. The chorda tympani nerve, which runs very close to the ear, carries taste information from the tongue to the rostral nucleus of the solitary tract and could be damaged by the ear bars of the stereotaxic frame. Cannulae were implanted with standard stereotaxic techniques and anchored to the skull via jeweler's screws and dental acrylic. Guide cannulae were fitted with obturators. Obturators were loosened daily to ensure patency and habituate subjects to handling procedures. Animals were maintained on ad libitum food and water for at least 7 days following surgery to allow for recovery.
Apparatus
All behavioral testing occurred in the home cage. Intracranial infusions were conducted in a room adjacent to the vivarium.
2.1.4. Procedure 2.1.4.1 Experiment 1A: GT inactivation before Trial 1. Rats were adapted to a water access schedule allowing 15-min access in the morning and 15-min access four hours later. Water intake was measured to the nearest 0.5 ml. Once water intake was stable over a three-day period (i.e., no main effect of Group and no significant Group × Day interaction), taste neophobia trials began. Taste neophobia trials consisted of presenting 0.5% saccharin in place of morning water. Bilateral intracranial infusions were made 20-min before the first taste neophobia trial. For intracranial infusions (0.5 μl/side), cannulated rats were removed from the home cage for 6-min during which time they received, according to group assignment, an infusion of saline (Group Saline; n = 9), or the BM cocktail (1.0 mM baclofen hydrochloride and 0.1 mM muscimol hydrobromide; Group BM; n = 14). Infusions were made through an injector cannula (26 gauge; Plastics One) attached by polyethylene tubing (PE20; Braintree Scientific) to a microsyringe (10 μl; Hamilton) controlled by a syringe pump (KD Scientific). The infusion cannula remained in place for 2-min before and after the infusion, which was made at a rate of 0.25 μl/min. Rats in Group Anesthesia (n = 10) received a mock infusion (i.e., handling) and were then returned to the home cage. Each of the five taste neophobia trials were separated by two water only days.
Experiment 1B: GT inactivation after Trial 1. As in Experiment
1A, except cannulated rats (from Experiment 1A) were assigned to Group Saline (n = 9) or Group BM (n = 14) in a quasi-random fashion counterbalancing for prior experience. Group Anesthesia (n = 10) was once again subjected to handling as a mock infusion. Additionally, the taste stimulus was 0.0001 M (i.e., 0.1 mM) quinine, and the bilateral intracranial infusions occurred 5-min after the first quinine presentation. This follow-up experiment was conducted 7 days after the termination of Experiment 1A, during which the animals were maintained on the same water access schedule of 15-min each morning and afternoon.
Histology
All cannulated rats were deeply anesthetized with a mixture of ketamine and xylazine (120:15 mg/kg, IP) and perfused transcardially with phosphate buffered saline followed by a 10% formalin solution. Injector cannulae were inserted throughout the perfusion to establish a clear injector cannula tract in the fixed tissue. Subsequently, brains were extracted, stored in 10% formalin at 4°C, and transferred to a 20% sucrose solution 48-hours prior to coronal sectioning (50 μm) on a cryostat. Slices through the cannula tract were mounted on slides and stained for nissl bodies using cresyl violet. Cannula placements were evaluated by examining the tracts made by the guide and injector cannulae with the aid of a light microscope.
Data analysis
Intake was analyzed via mixed designs analysis of variance (ANOVA) using Statistica software (version 13, Dell Inc., 2015) and, where necessary, planned comparisons (i.e., simple main effects with adjusted error term taken from overall ANOVA). The α level was set at .05. For significant main effects the effect size is reported as a partial eta-squared ( p 2 ).
Experiment 2: Medial amygdala and taste neophobia: GABA agonists

Animals, surgery and apparatus
Thirty-four rats were acquired as in Experiment 1A. Surgery was conducted as described above, except 27 rats had cannula implanted targeted 2 mm dorsal to the MeA (AP −2.5, ML ± 3.2, DV −6.1) and 7 rats formed the second control subgroup (Group Anesthesia). The experiment was conducted in the home cage.
Procedure
As in Experiment 1A, except Group Saline contained 12 subjects and Group BM contained 15 subjects.
Histology and data analysis
As in Experiment 1.
Experiment 3: Medial amygdala and taste neophobia: Chemogenetics
Animals and surgery
Thirty-five experimentally naïve rats were acquired as in Experiment 1A. General surgical procedures were identical to Experiment 1A except isoflurane (1-4%) was used for anesthesia. Rats were randomly assigned to three groups according to surgical treatment. A viral vector was infused bilaterally into the MeA (0.5 μl/site; Site 1, AP −2.0, ML ± 3.1, DV −8.3; Site 2, AP −3.0, ML ± 3.4, DV −8.5). Experimental groups were defined by the nature of the genetic material contained in each virus. Group Excitation (n = 12) was transfected with a virus encoding an excitatory chemogenetic receptor (AAV-hSyn-hM3D(Gq)-mCherry; UNC Vector Core, Chapel Hill, NC). Group Inhibition (n = 12) was transfected with a virus encoding an inhibitory chemogenetic receptor (AAV-hSyn-hM4D(Gi)-mCherry; UNC Vector Core). Finally, the Control group (n = 11) contained 6 animals (Group EGFP) infected with a virus encoding a benign fluorescent reporter (AAV-hSyn-EGFP; UNC Vector Core) to control for non-specific effects of neuronal viral infection, as well as 5 animals (Group Anesthesia) that were anesthetized and placed in the stereotaxic frame but received no surgical manipulation. Viral infusions were made using the same general infusion equipment as in Experiment 1A, except for the infusion rate was changed to 0.05 μl/min to minimize the spread of the virus beyond the target structure.
Apparatus
Behavioral testing was conducted in eight drinking chambers (Med Associates ENV-008), which were each 30.5 cm long × 24.1 cm wide × 29.2 cm high with modular aluminum sidewalls and clear polycarbonate doors, ceilings, and back walls. Steel bar floors were electrically connected through a lickometer circuit to a retractable spout that in the extended was positioned ∼3 mm outside the drinking chamber but was accessible for licking via an oval access hole (1.3 cm wide × 2.6 cm high at 6.0 cm above the floor) in the right-side chamber wall. The lickometer circuit (0.3 µA) was used to monitor individual licks with a temporal resolution of 10 ms. Each chamber was housed within a sound-attenuating cubicle equipped with a ventilation fan, white noise generator (∼80 dB), and a shaded light bulb (100 mA, 28 V) providing diffuse illumination. Chambers were connected to a computer in an adjacent room that controlled all events and recorded data using custom programs written in the Medstate notation language (Med Associates).
Procedure
Following 3 weeks to recover from surgery the rats were placed on a deprivation schedule that allowed 15-min access to water in both the morning (in the drinking chambers) and the afternoon (in the home cages). Water intake was assessed by weighing the bottles before and after each access period with a resolution of 0.1 g. Animals spent 3 weeks acclimating to the water deprivation schedule and reaching stable water intake baselines in the drinking chambers. Thus, chemogenetic receptors were allowed 6 weeks after surgery for expression before taste neophobia trials commenced. Each trial involved 15-min access to 0.15% saccharin once every third day during the morning drinking period. Forty-five minutes before Trial 1 all rats were injected with CNO (4 mg/ml/kg, IP), and then on each subsequent trial with vehicle (0.5% DMSO in physiological saline, 1 ml/kg, IP). CNO doses in the range of 1-3 mg/kg are common (Roth, 2016) . We intentionally used a high dose of CNO to ensure that parameters were optimized for the detection of an effect, which, if present, could be refined in later experiments by titrating the CNO dose. Volume consumed and lick times were recorded.
Histology and data analysis
As in Experiment 1, except tissue was examined for fluorescence (i.e., mCherry in groups Excitation and Inhibition or EGFP in group Control) marking infected cells. In addition to intake, lick cluster size was analyzed using the same statistical approach employed in Experiment 1A.
Results
Experiment 1: Gustatory thalamus and taste neophobia
Anatomical
Four subjects were dropped from statistical analyses due to misplaced cannula tips, which were found to be caudal to the GT. Guide cannulae caused damage to several structures dorsal to the GT; however, any behavioral effect of damage to these structures would be expected to produce a difference between cannulated control animals (Group Saline) and neurologically intact control animals (Group Anesthesia)-no such differences were found. Fig. 1 depicts the position of injection cannula tips (inverted triangles) targeting the GT of all subjects included in statistical analyses.
Behavioral: Experiment 1A
On Trial 1, two subjects in Group BM failed to consume any saccharin thereby failing to engage in the experiment; these animals were dropped from the experiment. Statistical analyses of baseline water and experimental saccharin intake revealed no difference between the control groups Anesthesia (n = 10) and Saline (n = 8), which were collapsed to form group Control (n = 18) in all subsequent analyses. For the three days preceding Trial 1, a mixed-design ANOVA revealed no statistical difference in water intake (see Table 1 ) between Group Control and Group BM during the morning drinking session (ps > 0.05).
As shown in Fig. 2A , group Control displayed the normal pattern of taste neophobia performance by consuming relatively little of the novel saccharin solution on Trial 1, with intake increasing on subsequent trials and reaching asymptote across Trials 3-5. This pattern contrasts with the performance of the BM group (n = 9) that consumed twice as much saccharin on Trial 1 as the control group. Surprisingly, Group BM consumed an equivalent amount across Trials 1-3. On Trial 4 Group BM increased saccharin intake but performance remained lower than the Control group, a pattern that persisted on Trial 5. Statistical analyses confirmed these impressions. A mixed design ANOVA with Group as the between-subjects variable and Trial as the within-subjects variable revealed a main effect of Group, F(1, 25) Planned comparisons of the significant interaction revealed that Trial 1 saccharin intake in Group BM was significantly higher than Group Control (p < .05). On Trials 2-5 Group BM consumed significantly less saccharin than Group Control (ps < 0.05). Regarding within-group differences across Trials, Group Control significantly increased intake from Trial 1 to 2 (p < .05) and from 2 to 3 (p < .05) but showed stable intake (i.e., reached asymptote) on Trials 3-5 (ps > 0.05). In Group BM, intake was not statistically different across Trials 1-3 (ps > 0.05), increased from Trial 3 to Trial 4 (p < .05) and was stable from Trial 4 to Trial 5 (p > .05). It is noted that during the conduct of this experiment (i.e., before subjects were dropped from the analysis for misplaced injector cannulae) Group Control and Group BM had reached the same asymptotic level of intake on Trials 4 and 5, at which time the experiment was terminated. Notably, the four animals with misplaced cannula with injector tips near, but caudal, to the GT showed behavior similar to the Control subjects, thereby increasing confidence that the effects observed in Group BM were due to inactivation of the GT.
Behavioral: Experiment 1B
There were no statistical differences between the two control subgroups Anesthesia (n = 10) and Saline (n = 7) so they were collapsed into Group Control (n = 17) for all analyses. Baseline water intake is summarized in Table 1 ; a two-way ANOVA of the data from which these means were derived showed that performance was stable over the 3 days prior to Trial (ps > .05).
An inspection of the results of Experiment 1B shown in Fig. 2B indicates equivalent Trial 1 performance between groups (i.e., before the BM infusion) with a Trial 2 increase in Group Control but a notable decrease in Group BM (n = 12). Statistical analyses confirmed these impressions. A repeated measures ANOVA revealed a significant Group main effect, F(1, 27) = 16.44, p < .05, p 2 = 0.378, Trial main effect, F (2, 54) = 4.07, p < .05, p 2 = 0.131, and Group × Trial interaction, F (2, 54) = 12.60, p < .05, p 2 = 0.318. The significant interaction was followed up with planned comparisons. On Trial 1, there was no statistical difference in quinine intake between groups Control and BM (F < 1). In the Control group, quinine intake significantly increased on Trial 3 relative to Trial 1 (p < .05). On the other hand, in Group BM, quinine intake decreased from Trial 1 to Trial 2 (p < .05) and was not statistically different on Trials 2 and 3 (p > .05). Finally, on Trials 2 and 3 Group BM consumed significantly less quinine than Group Control (ps < 0.05).
Experiment 2. Medial amygdala and taste neophobia: GABA agonists
Anatomical
Seven subjects were dropped from the experiment due to misplaced cannula tips. Guide cannulae caused damage to several regions dorsal to the MeA. If damage to any of these regions influenced the behavior of interest such an effect would be observed as a difference between the Anesthesia and Saline control subgroups. Fig. 3 depicts the placement of injector cannula tips (inverted triangles) targeting the MeA of all subjects included in statistical analyses.
Behavioral
One subject did not consume any saccharin on Trial 1. As with the two animals in Experiment 1A, this rat was dropped from the experiment. Analyses of the Anesthesia (n = 7) and Saline (n = 9) subgroups data revealed no differences in behavior regarding either water or saccharin intake; thus, these subgroups were collapsed to form Group Control (n = 16). Stable baseline water performance (see Table 2 ) was indicated by a lack of statistical difference between Group Control and Group BM (n = 10; ps > 0.05).
The results of the taste neophobia trials are summarized in Fig. 4 . Surveying the figure conveys the impression that there were no between-group differences in the occurrence and subsequent habituation of saccharin neophobia. Statistical analyses support these impressions. A mixed-design ANOVA revealed a significant main effect of Trial, F(3, 75) = 85.56, p < .05, p 2 = 0.774, but no effect of Group (F < 1) and no significant interaction (p = 0.067). Post-hoc tests of the Trial effect indicate that intake significantly increased from Trial 1 to Trial 2 (p < .05) and from Trial 2 to Trial 3 (p < .05) but not Trial 3 to Trial 4 (p > .05). So, each group expressed neophobia on Trial 1 that significantly habituated across Trials 2-4. Fig. 3 . The inverted triangles denote the placement of injector cannula tips in the subjects that provided data used in the statistical analyses of Experiment 2. Plate levels relative to bregma: A = −2.04, B = −2.28, C = −2.52, D = −2.76, E = −3.00, and F = −3.24 (Paxinos & Watson, 2007) .
Table 2
Baseline water consumption (in ml) from Experiment 2 for Group Control and Group BM. The intake data (mean ± SE) were obtained from the three days preceding Trial 1. 
Behavioral
The two control subgroups Anesthesia (n = 5) and EGFP (n = 6) were not statistically different (ps > 0.05) on any of the dependent measures and were thus collapsed into Group Control (n = 11). To establish a stable baseline of performance between groups, morning water intake in the drinking chamber (see Table 3 ) was analyzed for the three days preceding Trial 1. Repeated measures ANOVAs of each dependent measure found no significant main effect of Group and no Group × Trial interaction (ps > 0.05). However, there was a main effect of Trial for intake, F(2,62) = 24.92, p < .05, but not lick cluster size (p > .05). Thus, there were no significant between-groups differences in water intake prior to the initiation of experimental procedures.
In Fig. 6A , the normal occurrence and habituation of taste neophobia can be seen in Group Control as evidenced by low Trial 1 intake relative to asymptotic performance on Trials 2, 3 and 4. The administration of CNO on Trial 1 or the vehicle on subsequent trials does not appear to have influenced the occurrence or habituation of taste neophobia based on comparisons with control groups from prior studies (e.g., Arthurs & Reilly, 2013) . Relative to Trial 1 performance in the Control group, Group Excitation (n = 8) also showed normal taste neophobia but Group Inhibition (n = 8) displayed an exaggerated neophobic response (i.e., lower intake). On Trial 2 Group Excitation consumed less saccharin than Group Control, whereas Group Inhibition increased intake on Trial 2, relative to Trial 1. On Trials 3 and 4 there appear to be no between groups differences on intake. Statistical analyses confirm these impressions. That is, a repeated measures ANOVA revealed a significant main effect of Group, F(2,24) = 5.02, p < .05, p 2 = 0.295, Trial, F(3,72) = 29.13, p < .05, p 2 = 0.548, and a significant Group × Trial interaction, F(6,72) = 3.06, p < .05, p 2 = 0.203. Planned comparisons of the interaction were conducted to clarify interpretation of the pattern of results. Addressing the Control group data first, there was a significant increase in saccharin intake from Trial 1 to Trial 2 (p < .05), but there was no difference between intake on Trials 2-4 (Fs < 1). Intake in Group Excitation was not significantly different from the Control group on Trial 1 (F < 1). However, on Trial 2 Group Excitation consumed significantly less saccharin than Group Control (p < .05). Then, on Trials 3 and 4 intake in Group Excitation was not significantly different from Group Control (Fs < 1). Thus, Group Excitation showed normal taste neophobia on Trial 1, and a delay in the habituation of taste neophobia on Trial 2 relative to the Control group before reaching a common asymptote on Trials 3 and 4. Group Inhibition consumed significantly less saccharin than Group Control on Trial 1 (p < .05). On Trials 2-4 there was no statistical difference between Groups Control and Inhibition (p > .05). Thus, Group Inhibition consumed significantly less saccharin than the Control group on Trial 1 but not at asymptote.
As shown in Fig. 6B , the Control group had a neophobic reaction to saccharin demonstrated as low lick cluster size on Trial 1 relative to performance on Trials 2-4 -the expected pattern for normal rats (e.g., Arthurs & Reilly, 2013; Lin et al., 2012a) . Group Excitation performed like Group Control on Trial 1 but cluster size did not increase across Trials 1-4 for these rats. Cluster size on Trial 1 for Group Inhibition was approximately half that of Group Control but thereafter performance of both groups was equivalent, except on Trial 3. Statistical analysis showed a significant main effect of Group, F(2, 24) = 4.50, p < .05, were no significant within-group differences in cluster size across all 4 trials (ps > 0.05). As an indication of exaggerated neophobia, Group Inhibition had significantly smaller lick clusters on Trial 1 than Group Control (p < .05). Thereafter, cluster size significantly increased from Trial 1 to Trial 2 (p < .05) and was not statistically different across Trials 2-4 (ps > 0.05) for Group Inhibition. However, lick cluster size was significantly smaller for Group Inhibition than Group Control on Trial 3 (p < .05).
Discussion
The aim of the present study was to examine the roles of the GT and MeA in taste neophobia, an innate aversive phenomenon that occurs on first exposure to a novel taste (e.g., Lin et al., 2012a) . Thus, the temporary modulation of activity in the target areas was intentionally timed to influence performance on Trial 1; it is assumed that neural activity in the GT and MeA was normal on all subsequent taste trials. Accordingly, our primary interest is on performance during the initial taste exposure. The results were clear and straightforward. Pharmacological inhibition of the GT attenuated taste neophobia (Experiment 1A) but the same neural manipulation of the MeA appeared to have no influence on performance (Experiment 2). In Experiment 3, chemogenetic excitation of MeA neurons did not affect taste neophobia but chemogenetic inhibition of MeA neurons enhanced the magnitude of the normal taste neophobia reaction, expressed as significantly lower palatability and lower intake of the novel saccharin solution relative to that shown by the control subjects.
Lesions of either the GT or MeA attenuate taste neophobia (Arthurs & Reilly, 2013; Lin et al., 2009 ) but have no influence on taste perception (e.g., Reilly & Pritchard, 1996a) or CTA acquisition (Arthurs & Reilly, 2013; Reilly & Bornovalova, 2005) , which combined with the current results encourages the view that the GT and MeA may be involved in responding to the innate threat of taste neophobia. A different pattern of results has emerged for the BLA and GC. We have argued that the BLA and GC form a functional unit that is involved in processing the danger conveyed by a taste stimulus Lin, Arthurs, & Reilly, 2015 . Thus, we see a differentiation in the behavioral deficits produced by disrupting the BLA-GC functional unit versus either the GT or MeA: BLA-GC lesions disrupt the response to both innate and learned taste threats, whereas the GT and MeA seem to be involved in processing only innate threats. The present finding that BM infusions into the GT attenuate taste neophobia indicates that neuronal excitation in the GT is critical for the expression of taste neophobia whereas the finding that chemogenetic inhibition of MeA neurons enhanced the expression of taste neophobia indicates that taste neophobia relies on the inhibition of neurons within the MeA.
On the second taste exposure of Experiment 1A the experimental animals failed to increase their intake of saccharin, a level of performance that was significantly lower than that of the control group. One potential interpretation of this pattern of results is that BM infused into the GT may somehow have functioned as a US and supported the acquisition of a mild CTA. This notion was tested in a follow-up experiment in which BM was infused into the GT after ingestion of a novel quinine solution. That sequence of stimuli was employed because the development of a CTA is more likely with forward (CS before US) than backward (US before CS, as in Experiment 1A) pairings (e.g., Boland, 1973; Huang & Hsiao, 2008) . The results of Experiment 1B provide evidence that BM infused into the GT can support CTA acquisition. Although such a CTA may explain the level of performance of the BM group on Trials 2-5 of Experiment 1A, it is, of course, not relevant to our understanding of performance on Trial 1 of Experiment 1A. Furthermore, one might think the results of Experiment 1B implicate the GT as part of the neural substrates of CTA. We do not believe this to be the case because there are numerous reports showing that bilateral lesions of the GT have no influence on CTA acquisition (Arthurs & Reilly, 2013; Flynn, Grill, Schulkin, & Norgren, 1991; Mungarndee, Lundy, & Norgren, 2006; Reilly, Bornovalova, Dengler & Trifunovic, 2003; Reilly & Pritchard, 1996b; Scalera, Grigson & Norgren, 1997 ; for a review see Reilly, 1998) . In other words, the course of taste aversion learning is unaffected by the permanent absence of GT neurons. Although they may not advance our understanding of the role of the GT in taste neophobia, the results of Experiment 1B are important because they indicate that intracranial infusions of BM have a previously unsuspected influence on behavior, an influence that clearly is evident following consumption of a novel taste stimulus. In Experiment 2, contrary to our prediction, there was no statistical difference in Trial 1 saccharin intake between controls and MeA BMtreated animals. However, there was a numerical difference in the hypothesized direction (i.e., elevated intake in the BM treated animals) and a trend toward a significant interaction, which raises the question of whether this result is a false negative. While Experiment 2 had relatively large group sizes and appears sufficiently powered, some design choices need to be discussed. The MeA is a rather long structure in the rostrocaudal axis and was targeted with two viral injections in each hemisphere in Experiment 3, as we have done previously for excitotoxic lesions (e.g., . However, in Experiment 2 we implanted a single guide cannula in each hemisphere targeted to the center of the MeA. We chose this approach for several reasons. Specifically, we were concerned that using two cannula per hemisphere would have negative effects including increasing the risk of mechanical lesions of the MeA and doubling the risk of cannula misplacements. Thus, we are left to speculate if the null effect in Experiment 2 is real or the consequence of sub-optimal inactivation of the MeA, which produced a sub-maximal influence on behavior. Irrespective, given the results of Experiment 3, one direction for future studies might best focus on trying to parse out the specific neuronal population (i.e., the genetic identity) and neuroanatomical connectivity of MeA neurons involved in taste neophobia. Another interesting aspect of the MeA that will require further study is potential sex differences in the function of the MeA, which is sexually dimorphic in rats (Cooke & Woolley, 2005; Hirsch et al., 2018; Zancan, da Cunha, Schroeder, Xavier, & Rasia-Filho, 2018) .
In Experiment 3, we found that chemogenetic inhibition of cells within the MeA enhanced taste neophobia. This gain of function caused by chemogenetic inhibition supports our hypothesis, based on prior lesion and Fos studies Lin et al., 2012b) , that inhibition of neurons in the MeA drives taste neophobia. Thus, it seems that lesions of the MeA attenuate taste neophobia by destroying a neuronal population in the MeA that is responsible for driving the expression of taste neophobia. Unfortunately, the null effect in Experiment 2 is subject to some doubt due to the possibility that the pharmacological inhibition of the critical population of MeA neurons responsible for taste neophobia was suboptimal. Thus, it is difficult to speculate on potential roles for GABAergic signaling within the MeA in taste neophobia. Based on the results of Experiment 3, we hypothesize that inhibition of some population of neurons in the MeA results in disinhibition of a population of neurons outside the MeA resulting in enhanced taste neophobia. A potential future experiment to test this hypothesis would be to repeat Experiment 3 with a more selective manipulation in which inhibitory chemogenetic receptors are expressed selectively in GABAergic cells of the MeA. Such an experiment coupled with an examination of Fos expression in structures downstream of the MeA could reveal another node in the neural circuitry of taste neophobia. In mice, several efferent projections from the MeA have been identified including the central nucleus of the amygdala, bed nucleus of the stria terminalis, substantia innominata, and hypothalamus (e.g., Pardo-Bellver, Cádiz-Moretti, Novejarque, Martine-Garcia, and Lanuza, 2012) .
The most intriguing finding of the present study is that chemogenetic-induced inhibition of the MeA enhanced the neophobic reaction to a novel taste. To our knowledge, this is the first instance of a neural manipulation exaggerating the magnitude of the taste neophobia response. Taste neophobia habituates (i.e., palatability increases) as the novel edible becomes recognized as familiar and safe over repeated benign exposures. This is the normal process by which new foods are assimilated into a healthy diet. However, problems may arise if there is an exaggerated neophobic response such that the taste of the novel edible is perceived as so unpalatable, that, irrespective of the post-ingestive consequences, the edible is never sampled again. This is where taste neophobia can become maladaptive and where palatability, perceived as abnormally low, exerts a powerful negative influence on food intake and dietary selections that, inevitably, leads to malnutrition and ill health. There are, unfortunately, many clinical conditions where low palatability is a major concern, as indicated in eating disorders (e.g., Reilly, 2018a) . For examples, exaggerated taste neophobia undoubtedly plays a role in aspects of avoidant/restrictive food intake disorder (e.g., Dovey, 2018) and has a major influence on the feeding behavior of individuals with special needs, including autism (e.g., Kral, 2018; Williams & Seiverling, 2018) . A better understanding of the neural circuits and mechanisms of taste neophobia may provide a platform for the development of treatments and interventions that will benefit these clinical populations.
